JP2025506488A5 - - Google Patents

Info

Publication number
JP2025506488A5
JP2025506488A5 JP2024547510A JP2024547510A JP2025506488A5 JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5 JP 2024547510 A JP2024547510 A JP 2024547510A JP 2024547510 A JP2024547510 A JP 2024547510A JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5
Authority
JP
Japan
Prior art keywords
sequence
seq
sequence identity
identity
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506488A (ja
Filing date
Publication date
Priority claimed from GBGB2209454.4A external-priority patent/GB202209454D0/en
Application filed filed Critical
Priority claimed from PCT/GB2023/050281 external-priority patent/WO2023152486A1/en
Publication of JP2025506488A publication Critical patent/JP2025506488A/ja
Publication of JP2025506488A5 publication Critical patent/JP2025506488A5/ja
Pending legal-status Critical Current

Links

JP2024547510A 2022-02-09 2023-02-08 治療抗体 Pending JP2025506488A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB202201674 2022-02-09
GB2201674.5 2022-02-09
GB2209454.4 2022-06-28
GBGB2209454.4A GB202209454D0 (en) 2022-06-28 2022-06-28 Therapeutic antibodies
PCT/GB2023/050281 WO2023152486A1 (en) 2022-02-09 2023-02-08 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
JP2025506488A JP2025506488A (ja) 2025-03-11
JP2025506488A5 true JP2025506488A5 (cg-RX-API-DMAC7.html) 2026-01-30

Family

ID=85283675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547510A Pending JP2025506488A (ja) 2022-02-09 2023-02-08 治療抗体

Country Status (11)

Country Link
US (1) US20250340659A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476256A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506488A (cg-RX-API-DMAC7.html)
KR (1) KR20240139085A (cg-RX-API-DMAC7.html)
AU (1) AU2023219227A1 (cg-RX-API-DMAC7.html)
CA (1) CA3258958A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002361A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010901A2 (cg-RX-API-DMAC7.html)
IL (1) IL314314A (cg-RX-API-DMAC7.html)
MX (1) MX2024009898A (cg-RX-API-DMAC7.html)
WO (1) WO2023152486A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EA032389B1 (ru) * 2012-02-14 2019-05-31 Мериал, Инк. Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
JP7449234B2 (ja) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー 獣医学使用のためのインターロイキン31モノクローナル抗体
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies

Similar Documents

Publication Publication Date Title
JP2023540444A5 (cg-RX-API-DMAC7.html)
US20250122301A1 (en) Cd25 antibodies
JP2023179409A (ja) 二重特異性抗体
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP7254699B2 (ja) 抗bcma重鎖のみ抗体
CN101903402B (zh) 抗tl1a的人源化抗体
RU2014121043A (ru) Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2021515565A5 (cg-RX-API-DMAC7.html)
JP2021516974A5 (cg-RX-API-DMAC7.html)
JP2015502145A5 (cg-RX-API-DMAC7.html)
CN116239698A (zh) 双功能融合蛋白及其医药用途
KR102167261B1 (ko) 관절염 치료
JP2020511123A5 (cg-RX-API-DMAC7.html)
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
JP2020007318A5 (cg-RX-API-DMAC7.html)
CN104903352A (zh) 多价结合蛋白组合物
JP2023540444A (ja) 治療用抗体
Sadeghalvad et al. Introduction on monoclonal antibodies
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
JP2023550628A5 (cg-RX-API-DMAC7.html)
JP2011518857A (ja) 治療用のgm−csfおよびil−17阻害剤
JP2007501847A (ja) 自己/同種免疫状態の治療用抗FcRn抗体
JP2016501877A5 (cg-RX-API-DMAC7.html)
CN118165106A (zh) 抗犬il-31单克隆抗体及其应用